Stock Sale, Buyback News

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM     1. Details of the p...

PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with Article 5 of EU Regulation n° 596/2014 (Market Abuse Regulation), detailed information is available on the website of Tikehau Capital (Paris:TKO): https://www.tikehaucapital.com/fr/shareholders/regulatory-information Name of the issuer Issuer Identity Code (LEI) Trading Day ISIN Aggregated volume per day (number of shares) Weighted average price per day Market (MIC Code) TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 21/11/2025 FR0013230612 4 09...

TORONTO--(BUSINESS WIRE)--dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL) announced today that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. LLC (“Glass Lewis”) have each recommended that the Company’s shareholders vote FOR the special resolution (the “Arrangement Resolution”) to approve the previously announced proposed plan of arrangement transaction whereby a newly formed acquisition vehicle controlled...

LONDON & DENVER & JOHANNESBURG--(BUSINESS WIRE)--AngloGold Ashanti plc (the “Company”) (NYSE: AU; JSE: ANG) announces that an Executive Director, Gillian Doran, has dealt in securities of the Company. Following the sale, Ms. Doran continues to hold 51,271 shares and share incentive scheme awards, and another 89,738 shares under the Performance Share Plan that have not yet vested. Name of Executive Director Gillian Doran Name of Company AngloGold Ashanti plc Date of transaction 24 November 2025...

LOS ANGELES--(BUSINESS WIRE)--Capstone Green Energy Holdings, Inc. (the "Company” or “Capstone”) (OTCQX: CGEH), together with its subsidiaries, a leading provider of clean technology solutions using ultra-low-emission microturbine energy systems, today announced the closing of its previously announced private investment in public equity financing (the “PIPE”), resulting in gross proceeds of approximately $15 million (before fees and expenses). The Company issued an aggregate of 7,500,000 shares...

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM   1. Details of the person discharg...

ENGLEWOOD, Colo.--(BUSINESS WIRE)--GCI Liberty Announces Terms for Previously Announced Rights Offering...

DALLAS--(BUSINESS WIRE)--FrontView REIT (“FrontView” or the “Company”) (NYSE:FVR) today announced that its Board of Directors has authorized the repurchase of up to $75 million of its outstanding common stock under a stock repurchase program. The authorization will expire on November 10, 2026. The stock repurchase program is intended to be implemented through purchases made from time to time using a variety of methods, which may include open market purchases, privately negotiated transactions o...

SANTA ROSA, Calif.--(BUSINESS WIRE)--Keysight Technologies, Inc. (NYSE: KEYS) today reported financial results for the fourth fiscal quarter and fiscal year ended October 31, 2025. “Keysight delivered an outstanding quarter and strong close to the fiscal year, returning the company to full-year growth with order momentum accelerating through the year,” said Satish Dhanasekaran, Keysight’s President and CEO. “These results reflect our leadership across the markets we serve and sustained demand f...

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s B...